Research map: Empirical-Null Calibration Challenges Comparative CNS Safety Signals for Androgen-Receptor Pathway Inhibitors: A FAERS Re-Analysis

Back to the article

Papers in this map

  1. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions · Eugène van Puijenbroek · 2002 · 1392 citations · Cited by this paper
  2. Sarcosine-Based Pharmacokinetic Optimization and Fluorescent Dye Library Evaluation of Dual-Labeled PSMA Inhibitors for Fluorescence-Guided Surgery · 2026 · Related
  3. Risk of Fracture after Androgen Deprivation for Prostate Cancer · Vahakn B. Shahinian · 2005 · 1381 citations · Cited by this paper
  4. Antibody–Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors · 2026 · Related
  5. Interpreting observational studies: why empirical calibration is needed to correct p‐values · Martijn J. Schuemie · 2013 · 249 citations · Cited by this paper
  6. Fucoidan Ameliorates Contrast-Induced Acute Kidney Injury in Mice by Modulating the TLR4/NF-κB and Nrf2/GPX4 Pathways · 2026 · Related
  7. The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010 · Keith B. Hoffman · 2014 · 204 citations · Cited by this paper
  8. Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound–Indication Matching and Precision Neurotherapeutic Development · 2026 · Related
  9. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data · Martijn J. Schuemie · 2018 · 174 citations · Cited by this paper
  10. Potential Adjunctive Effects of Quercetin–Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study · 2026 · Related
  11. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer · Irbaz Bin Riaz · 2023 · 131 citations · Cited by this paper
  12. Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK · 2026 · Related
  13. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors · Zin War Myint · 2020 · 61 citations · Cited by this paper
  14. False Novelty in Antibacterial Natural-Product Discovery: Rediscovery, Structural Misassignment, and a Checkpoint Framework for Early Verification · 2026 · Related
  15. Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial · Steven Williams · 2023 · 36 citations · Cited by this paper
  16. ELOVL6: A Key Factor in the Gender Differences of Olanzapine-Induced Weight Gain · 2026 · Related
  17. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis · Silke Gillessen · 2025 · 35 citations · Cited by this paper
  18. Continuous Inhibition-Zone Modeling and Binary Classification for Pseudomonas aeruginosa Hit Prioritization: A Retrospective QSAR Evaluation · 2026 · Related
  19. Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials · Craig Henry Jones · 2024 · 30 citations · Cited by this paper
  20. Complementary Time-Kill Activity Displayed by Povidone-Iodine and Hydrogen Peroxide Against Shoulder Arthroplasty–Associated Pathogens, Envisaging Intraoperative Irrigation · 2026 · Related
  21. The value of time‐to‐onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands · Joep H. G. Scholl · 2016 · 25 citations · Cited by this paper
  22. The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline · Michele Fusaroli · 2024 · 15 citations · Cited by this paper
  23. Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS) · Yang Liu · 2023 · 13 citations · Cited by this paper
  24. Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis · Akihiro Matsukawa · 2024 · 12 citations · Cited by this paper
  25. A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database · Haiwei Xiao · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)